Roche says Tecentriq combination cuts lung cancer risk

ZURICH (Reuters) - A late-stage trial of Roche's immuno-oncology medicine Tecentriq with other cancer drugs as an initial therapy for lung cancer met its goal of significantly reducing the risk of disease worsening or death, the Swiss drugmaker said on Monday.